The Russian Direct Investment Fund (RDIF) is considering the possibility of investing in several more Favipiravir-based drugs, Chief Executive Officer Kirill Dmitriev said on Thursday.
“Two more companies are finalizing clinical trials of Favipiravir-based drugs in Russia — our portfolio company R-Pharm and Promomed company, which will virtually produce Favipiravir-based drugs. We support those companies and plan to invest in production of those drugs,” he said.
Clinical trials of Favipiravir are currently underway across the world, particularly India’s Glenmark has received registration already, whereas Turkey is undergoing registration now, the CEO added.
Avifavir is the first Favipiravir-based drug in the world approved for treatment of COVID-19. It has shown high efficacy in clinical trials, disrupting the reproduction mechanisms of coronavirus. Its deliveries to Russian hospitals started on June 11, test batches have also been supplied to Belarus, and deliveries to Brazil, Mexico and Chile are planned.
Header: MOSCOW, RUSSIA – MAY 29, 2020: Staff members at work in the ‘red zone’ of a temporary medical facility established for COVID-19 patients at Moscow City Clinical Hospital No 15 (Filatov Hospital). Sergei Bobylev/TASS
Favipiravir, sold under the brand name Avigan or Abigan, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections.
Like the experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative.
It is being developed and manufactured by Toyama Chemical (Fujifilm group) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensed API for it to Zhejiang Hisun Pharmaceutical Co. of China. It became a generic drug in 2019.